Abstract: A vitamin D.sub.3 analogue having at least one hydroxyalkyl substituent on the A-ring, preferably the 1-position which is useful in inhibiting cell proliferation.

Abstract: The invention relates to a new process for obtaining a completely pure oxytetracycline which does not contain any acetyldecarboxamidooxytetracycline as ingredient. In glacial acetic acid there is suspended under stirring oxytetracycline hydrochloride, or alternatively, oxytetracycline dihydrate under addition of an equimolar quantity of hydrogen chloride in the form of concentrated hydrochloric acid. The stirring is continued for 5 hours, the formed oxytetracycline hydrochloride acetate precipitate is filtered, washed with glacial acetic acid and acetone, whereupon it is dried under reduced pressure at a temperature up to 40.degree. C. till constant weight. Oxytetracycline hydrochloride acetate ##STR1## is a new compound and may be used as intermediate in the above process.

Abstract: The present invention relates to compounds of formula (I) ##STR1## in which R.sup.1 and R.sup.2 may be the same or different and stand for hydrogen, lower alkyl, lower cycloalkyl, or, taken together with the carbon atom (starred in formula I), bearing the groups X, R.sup.1 and R.sup.2, can form a C.sub.3 -C.sub.8 carbocyclic ring; X stands for hydrogen or hydroxy, R.sup.3 and R.sup.4, which may be the same or different stand for hydrogen, lower alkyl or halogen, n is 0, 1 or 2 and m is 0, 1 or 2. The present compounds, which find use both in the human and veterinary practice, show an immunomodulating effect as well as strong activity in inducing differentiation and inhibiting undesirable proliferation of certain cells, including cancer cells and skin cells.

Abstract: A quinone derivative useful in the treatment of hepatic diseases defined by the general formula: ##STR1## where X and Y may be the same or different from each other and are each a hydroxyl group, a group represented by the formula --(--OCH.sub.2 --).sub.n --OR.sup.6, wherein n is 0 or 1 and R.sup.6 is a lower alkyl group, or an acyl group.

Abstract: The invention provides compounds of the formula: ##STR1## wherein R, R.sup.3, R.sup.4, X and W are defined in the specification. These compounds are useful as antibiotic agents.

Abstract: 21-norvitamin D.sub.3 analogs in which the methyl group normally attached to the side chain at carbon 20 has been replaced by a hydrogen atom. The compounds are characterized by a marked intestinal calcium transport activity while exhibiting much lower activity than 1.alpha.,25-dihydroxyvitamin D.sub.3 in their ability to mobilize calcium from bone. Because of their preferential calcemic activity, these compounds are useful for the treatment of diseases where bone formation is desired, such as osteodystrophy. Novel intermediates formed during the synthesis of the end products are also disclosed.

Abstract: This invention is for 1.alpha.-fluoro-25-hydroxy-16-ene-23-yne-cholecalciferol, which can be further characterized by the formula: ##STR1## and which is useful as an agent for the treatment of sebaceous gland diseases such as acne and sebhorreic dermatitis.

Abstract: The invention provides compounds of the formula: ##STR1## wherein R, R.sup.3, R.sup.4 and W are defined in the specification. These compounds are useful as antibiotic agents.

Abstract: Biologically active 1.alpha.-hydroxy-22-iodinated vitamin D.sub.3 compounds and a process for the preparation of 1.alpha.-hydroxy-22-iodinated vitamin D.sub.3 compounds are disclosed. The 22-iodo-vitamin D.sub.3 compounds show relatively high binding affinity for the vitamin D receptor demonstrating their potential for high in vivo biological activity. Further, these compounds induce relatively high differentiation of malignant cells. Also, these 22-iodo compounds show high in vivo calcium transport activity with little or no bone calcium mobilization activity. These compounds thus show promise in the treatment of osteoporosis.

Abstract: The invention relates to compounds of formula I ##STR1## in which formula X is hydrogen or hydroxy; Y is oxygen, sulphur, or oxidized sulfur (S(O) or S(O.sub.2)); R.sup.1 and R.sup.2, which may be the same or different, stand for hydrogen or C.sub.1 -C.sub.6 hydrocarbyl, or R.sup.1 and R.sup.2, taken together with the carbon atom (starred in formula I) bearing the group X, form a C.sub.3 -C.sub.8 carbocyclic ring; Q is a C.sub.1 -C.sub.8 hydrocarbylene diradical. R.sup.3 is hydrogen or C.sub.1 -C.sub.6 hydrocarbyl. R.sup.1, R.sup.2 and/or Q, may be optionally substituted with one or more deuterium or fluorine atoms; n is 0 or 1. The present compounds show antiinflammatory and immunomodulating effects as well as a strong activity in inducing cell differentiation and inhibiting undesirable proliferation of certain cancer and skin cells.

Abstract: Vitamin D.sub.2 analogs in which a cyclopentane ring is introduced into the side chain of 1.alpha.,25-dihydroxyvitamin D.sub.2 The compounds are characterized by a marked intestinal calcium transport activity while exhibiting much lower activity than 1.alpha.,25-dihydroxyvitamin D.sub.3 in their ability to mobilize calcium from bone. Because of their preferential calcemic activity, these compounds would be useful for the treatment of diseases where bone formation is desired, such as osteoporosis.

Abstract: Biologically active 1.alpha.-hydroxy-22-iodinated vitamin D.sub.3 compounds and a process for the preparation of 1.alpha.-hydroxy-22-iodinated vitamin D.sub.3 compounds are disclosed. The 22-iodovitamin D.sub.3 compounds show relatively high binding affinity for the vitamin D receptor demonstrating their potential for high in vivo biological activity. Further, these compounds induce relatively high differentiation of malignant cells. Also, these 22-iodo compounds show high in vivo calcium transport activity with little or no bone calcium mobilization activity. These compounds thus show promise in the treatment of osteoporosis.

Abstract: Pharmaceutical compositions are provided for lowering the activity of HMG-CoA reductase and/or lowering serum cholesterol, comprising an amount effective to lower the activity of HMG-CoA reductase and/or lower serum cholesterol of a side chain derivatized 15-oxygenated sterol having the formula (I): ##STR1## the basic ring structure being saturated or unsaturated, wherein R.sub.1 is --OH, .dbd.O, --OR.sub.7, ##STR2## a sulfate group, a sugar moiety, or a Mg, Na, or K salt of a sulfate group;R.sub.2 is --H, --OH, .dbd.O, mono- or di-halogen, or a C.sub.1 to C.sub.6 alkyl group, which may be unsaturated or substituted with halogen;R.sub.3 is --H, --OH, halogen, or a C.sub.1 to C.sub.6 alkyl group, which may be unsaturated or substituted with halogen;R.sub.4 is nonexistent when there is a double bond between the 8 and 14 carbons or .alpha.H, .beta.H, or an .alpha.C.sub.1 to C.sub.6 alkyl group;R.sub.5 is --OH, .dbd.O, .dbd.NOH, or ##STR3## R.sub.6 is --CH.sub.2 CH(CH.sub.3).sub.2 or CH.sub.2 N(CH.sub.3).sub.

Abstract: Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatic steroids and methods for their use in treating ocular hypertension, including controlling the ocular hypertension associated with primary open angle glaucoma, are disclosed. In addition, the combination of the compounds with glucocorticoids for the prevention of elevated IOP during the treatment of inflammation is disclosed.

Abstract: A novel process the preparation of pentaalkylchromenes of the general formula: ##STR1## wherein R denotes a lower alkyl group having 1 to 4 C atoms and R.sub.1 denotes a phenyl group which is unsubstituted or substituted by a lower alkyl group having 1 to 4 C atoms, by halogen or by a nitro group, or an alkanoyl group having 1 to 4 C atoms. In the process, a trialkylhydroquinone is reacted with a halogenated butenol to give a substituted tetraalkyhydroquinone, which is oxidized. Then the halogen atom is substituted with a suitable nucleophile and the compound is finally cyclized to give the final product. The pentaalkylchromenes are suitable intermediates for the preparation of hypolipidaemic pharmaceuticals.

Abstract: The disclosed invention includes corticoid-17-alkylcarbonates substituted in the 17-position, a process for their preparation and pharmaceuticals containing them. These corticoid-17-alkylcarbonates have the following formula I ##STR1## where A is CHOH in any desired steric arrangement, C.dbd.O or CH.sub.2 ; Y is H, F, or Cl; Z is H, F or CH.sub.3 ; R(1) is O-acyl, carbonylalkyl, alkylsulfonate or arylsulfonate;R(2) is branched alkyl or (CH.sub.2).sub.2-4 --OCH.sub.3 andR(3) is H or methyl. They have excellent local and topical antiinflammatory action. They are distinguished by a particularly good ratio of local to systemic antiinflammatory activity and in some cases also show stronger local antiinflammatory activities than their isomeric corticoid-17-alkylcarbonates having a linear alkyl group in the 17-alkylcarbonate moiety.

Abstract: The invention includes compounds of the following formula ##STR1## where A and B either A and B form an additional double bond and D is a hydrogen atom or B and D form an additional double bond and A is a hydrogen atom and the other variables are as defined in the specification. Also disclosed is a process of making the compounds and a process of using the compounds to make compounds of the following formula ##STR2## where the variables are defined in the specification. These compounds are useful as antigestigens.

Abstract: An estradiol derivative-chlorambucil conjugate of the formula (I): ##STR1## wherein R.sup.1 is alkyl or alkoxyl of 1 to 4 carbon atoms; R.sup.2 is acyl, dansyl, or alkyl; R.sup.3, R.sup.4, and R.sup.5 independently are H, oxo, OH, or acyloxy; m is an integer of 1 to 3; and n is an integer of 0 to 3; provided that when n is 0, all of R.sup.3, R.sup.4, and R.sup.5 are not H at the same time, and at least one of R.sup.3, R.sup.4, and R.sup.5 is a group other than H and OH; and further, when n is 2 or 3, the groups R.sup.1 are the same or different; a process for preparing the same, and a pharmaceutical composition containing the conjugate are described.

Abstract: In the process, a copper/rhodium catalyst impregnated with 0.1 to 10.0% by weight, based on the total weight of active charcoal catalyst support and active components, of a water-soluble phosphonium halide is employed for the preparation of trichloroelethylene from perchloroethylene and hydrogen.